Vertex Pharmaceuticals Inc
VRTX447.380USD
-2.140-0.48%
Cierre 12/18, 16:00（ET）Cotizaciones retrasadas 15 min
113.61BCap. mercado
31.27P/E TTM
Más Datos de Vertex Pharmaceuticals Inc Compañía
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Información de Vertex Pharmaceuticals Inc
Símbolo de cotizaciónVRTX
Nombre de la empresaVertex Pharmaceuticals Inc
Fecha de salida a bolsaJul 24, 1991
Director ejecutivoKewalramani (Reshma)
Número de empleados6100
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 24
Dirección50 Northern Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02210
Teléfono16173416393
Sitio Webhttps://www.vrtx.com/
Símbolo de cotizaciónVRTX
Fecha de salida a bolsaJul 24, 1991
Director ejecutivoKewalramani (Reshma)
Ejecutivos de Vertex Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
15.31K
-2.22%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
6.32K
-11.24%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.57K
-5.51%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
51.81K
+23.92%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
+12.50%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
25.80K
-14.85%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Duncan Mckechnie
Mr. Duncan Mckechnie
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
16.13K
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.83B
62.08%
Europe
910.90M
30.94%
Other
205.60M
6.98%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
TRIKAFTA
2.55B
86.65%
Other product revenues
205.70M
6.99%
ALYFTREK
156.80M
5.33%
CASGEVY
30.40M
1.03%
Estadísticas de accionistas
Actualizado: sáb., 15 de nov
Actualizado: sáb., 15 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Otro
63.49%
Accionistas
Accionistas
Proporción
Capital World Investors
10.21%
The Vanguard Group, Inc.
9.50%
Capital Research Global Investors
6.52%
BlackRock Institutional Trust Company, N.A.
5.70%
State Street Investment Management (US)
4.57%
Otro
63.49%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
60.06%
Investment Advisor/Hedge Fund
28.01%
Research Firm
2.35%
Pension Fund
2.27%
Bank and Trust
2.08%
Sovereign Wealth Fund
1.50%
Hedge Fund
1.14%
Individual Investor
0.14%
Insurance Company
0.09%
Otro
2.36%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
28.73M
11.21%
+198.84K
+0.70%
Jun 30, 2025
The Vanguard Group, Inc.
23.86M
9.31%
+479.23K
+2.05%
Jun 30, 2025
Capital Research Global Investors
16.11M
6.28%
+1.57M
+10.81%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
14.15M
5.52%
+156.31K
+1.12%
Jun 30, 2025
State Street Investment Management (US)
11.78M
4.59%
-13.43K
-0.11%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.93M
2.31%
+166.99K
+2.90%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
5.26M
2.05%
-18.59K
-0.35%
Aug 31, 2025
Wellington Management Company, LLP
4.81M
1.88%
-641.36K
-11.76%
Jun 30, 2025
Capital International Investors
2.64M
1.03%
+1.99M
+305.59%
Jun 30, 2025
AllianceBernstein L.P.
4.38M
1.71%
+424.81K
+10.75%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: vie., 5 de dic
Actualizado: vie., 5 de dic
Nombre
Proporción
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
Ver más
VanEck Biotech ETF
Proporción9.71%
ProShares Ultra Nasdaq Biotechnology
Proporción8.83%
Invesco Nasdaq Biotechnology ETF
Proporción8.76%
iShares Biotechnology ETF
Proporción7.43%
Invesco Biotechnology & Genome ETF
Proporción5.35%
Natixis Loomis Sayles Focused Growth ETF
Proporción4.48%
First Trust NASDAQ Pharmaceuticals ETF
Proporción4.23%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.5%
Franklin Genomic Advancements ETF
Proporción3.33%
Simplify Health Care ETF
Proporción3.25%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Vertex Pharmaceuticals Inc?
Los cinco principales accionistas de Vertex Pharmaceuticals Inc son:
Capital World Investors posee 28.73M acciones, lo que representa el 11.21% del total de acciones.
The Vanguard Group, Inc. posee 23.86M acciones, lo que representa el 9.31% del total de acciones.
Capital Research Global Investors posee 16.11M acciones, lo que representa el 6.28% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 14.15M acciones, lo que representa el 5.52% del total de acciones.
State Street Investment Management (US) posee 11.78M acciones, lo que representa el 4.59% del total de acciones.
Capital World Investors posee 28.73M acciones, lo que representa el 11.21% del total de acciones.
The Vanguard Group, Inc. posee 23.86M acciones, lo que representa el 9.31% del total de acciones.
Capital Research Global Investors posee 16.11M acciones, lo que representa el 6.28% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 14.15M acciones, lo que representa el 5.52% del total de acciones.
State Street Investment Management (US) posee 11.78M acciones, lo que representa el 4.59% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Vertex Pharmaceuticals Inc?
Los tres principales tipos de accionista de Vertex Pharmaceuticals Inc son:
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
Capital World Investors
The Vanguard Group, Inc.
Capital Research Global Investors
¿Cuántas instituciones poseen acciones de Vertex Pharmaceuticals Inc (VRTX)?
A fecha de 2025Q3, 2933 instituciones poseen acciones de Vertex Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 249.27M, lo que representa el 98.24% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -0.32%.
¿Cuál es la mayor fuente de ganancias de Vertex Pharmaceuticals Inc?
El FY2025Q2, el segmento empresarial TRIKAFTA generó la ganancia más alta para Vertex Pharmaceuticals Inc, ascendiendo a 2.55B y representando el 86.65% de la ganancia total.
